Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

2 COVID Vaccine Stocks With Key Results on the Way

By Keith Speights - Dec 19, 2020 at 7:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

More good news could be in store for early 2021.

One COVID-19 vaccine is already being given to Americans. Another could win Emergency Use Authorization in only a few days. But that's just the beginning of the news for COVID-19 vaccine makers. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights talk about two other COVID-19 vaccine stocks with key results on the way.

Corrine Cardina: My last topic for us before we try to tackle a couple of Slido questions is turning to the companies that are next in line to cross this finish line, what do we know about the timeline for Johnson & Johnson ( JNJ 1.46% ) and AstraZeneca's ( AZN -1.02% ) phase 3 data?

Keith Speights: Let's start with Johnson & Johnson. Johnson & Johnson has kept their information a little closer to the vest than a lot of these companies. I think it's reasonable to expect that J&J will report their interim results from their phase 3 study sometime early next year. I've said it before, I'll say it again. I'm extremely interested in seeing what their efficacy will be. We have news coming from J&J early in 2021.

AstraZeneca is a little interesting because they could have their data from their current studies available around the same time frame as Johnson & Johnson. However, keep in mind that the higher efficacy for AstraZeneca was in a group that received a half dose then a full dose of their vaccine.

They didn't have that dosing regimen in their US study originally. They said they were going to add that dosing regimen to their US study. But the FDA requires two months of observation after the second dose.

It's going to be interesting to see with AstraZeneca. That could throw them off somewhat if they're going to wait to file EUA with the FDA until they have results from the group that could give them a higher efficacy. I think the verdict is still out when it comes to AstraZeneca.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$159.38 (1.46%) $2.29
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.23 (-1.02%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.